All In Biotech

Drug Trial Radar · NCT00256204

A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease

A Multi Center, Double Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects

Last checked: Nov 20, 2026Latest source record: Jan 12, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,174 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,174

Actual

Start

Nov 2005

Primary completion

Apr 2008

Study completion Jun 2009

Sponsor

Sponsor type
Industry
First posted
Nov 21, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A 2 phase study to evaluate disease progression in Parkinson's disease patients taking rasagiline

Conditions

  • Parkinson's Disease

Interventions

  • Rasagiline MesylateDrug

    tablet, 1mg once daily

  • Rasagiline MesylateDrug

    tablet, 2mg once daily

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From BaselineTime frame: 12w, 24w, 36w, 42w, 48w, 54w, 60w, 66w, 72w

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.